On October 14, 2025, Rocket Pharmaceuticals, Inc. announced the FDA accepted the resubmission of their Biologics License Application for KRESLADI™, a gene therapy for a severe genetic disorder, with a decision date set for March 28, 2026. The company is eligible for a Rare Pediatric Disease Priority Review Voucher if approved.